Pfizer Inc.
PFE
Market Cap$149.15B
Close$
Earnings Call Q4 2023
January 30, 2024 - AI Summary
Pfizer reported full-year 2023 revenues of $58.5 billion, achieving 7% operational growth (excluding COVID products), in line with expectations.
The decline in revenue from COVID products significantly impacted the overall results, leading to a 41% year-over-year decrease in revenues.
Adjusted diluted earnings per share for 2023 were $1.84, down 72% compared to the previous year, primarily due to lower sales of Comirnaty and Paxlovid.
Exclusive for Stockcircle Pro members
Sign up
$63.23
146.1% upside
Current Fair Value
146.1% upsideUndervalued by 146.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $149.15 Billion |
|---|---|
| Enterprise Value | $208.35 Billion |
| Dividend Yield | $1.6166 (6.14%) |
| Earnings per Share | $0.37 |
| Beta | 0.37 |
| Outstanding Shares | 5,662,541,291 |
| Avg 30 Day Volume | 37,259,803 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 70.42 |
|---|---|
| PEG | -42.05 |
| Price to Sales | 2.57 |
| Price to Book Ratio | 1.71 |
| Enterprise Value to Revenue | 3.56 |
| Enterprise Value to EBIT | 41.05 |
| Enterprise Value to Net Income | 98 |
| Total Debt to Enterprise | 0.35 |
| Debt to Equity | 0.81 |
Revenue Sources
No data
ESG Score
No data
About Pfizer Inc.
CEO: Albert Bourla